Core Insights - In 2025, Hong Kong's IPO market achieved a record fundraising of $37.4 billion, marking a 231% year-on-year increase and surpassing the total of the previous three years combined [1] - The TMT sector led the market with $34.5 billion in issuance, while the healthcare and biotechnology sectors raised $15.6 billion, with biotechnology alone contributing $6.2 billion [1] - As of early February 2026, over 400 companies are queued for listing, with more than 50 targeting specific chapters of the listing rules, indicating a robust pipeline for the IPO market [1] IPO Performance - The top three companies by fundraising in 2025 were CATL ($41.0 billion), Zijin Mining International ($28.7 billion), and SANY Heavy Industry ($15.5 billion), primarily from sectors like renewable energy, AI, and healthcare [2] - The average first-day price increase for IPOs raising over $100 million was 23.8%, with an average one-month increase of 30.7%, representing the best performance in nearly two decades [4] Foreign Investment Trends - Long-term foreign investment in Hong Kong IPOs surged, with participation rates rising from 10%-15% in early 2024 to 85%-90% in 2025, with expectations to reach 90%-95% in 2026 [4][5] - Major global funds such as Morgan Stanley and Livermore Securities are leading the charge in foreign investments in Hong Kong IPOs [5] Sectoral Insights - The IPO pipeline for 2026 shows a significant focus on AI and software technology, with 22.88% of companies in this category, followed by healthcare and biotechnology at 17.75% [10] - The Hong Kong Stock Exchange has introduced measures to facilitate listings for tech companies, including a "special line" for tech firms and allowing confidential submissions [9] Notable Companies and Underwriters - The top underwriters for 2025 IPOs were CICC (41 projects), CITIC Securities (32 projects), and Huatai Securities (22 projects) [4] - The most anticipated companies for 2026 include Kunlun Chip, Shangmi Technology, and Qunke Technology, indicating a strong interest in new economy sectors [12]

Core Insights - In 2025, Hong Kong's IPO market achieved a record fundraising of $37.4 billion, marking a 231% year-on-year increase and surpassing the total of the previous three years combined [1] - The TMT sector led the market with $34.5 billion in issuance, while the healthcare and biotech sectors raised $15.6 billion, with biotech alone contributing $6.2 billion [1] - As of early February 2026, over 400 companies are lined up for IPOs, with more than 50 targeting specific chapters related to biotech and specialized technology [1] IPO Performance - The top three companies by fundraising in 2025 were CATL ($41.0 billion), Zijin Mining International ($28.7 billion), and SANY Heavy Industry ($15.5 billion), primarily from sectors like renewable energy, AI, and healthcare [2] - The average first-day price increase for IPOs raising over $100 million was 23.8%, with a one-month average increase of 30.7%, the best performance in nearly two decades [5] Foreign Investment Trends - Long-term foreign investment in Hong Kong IPOs surged, with participation rates rising from 10%-15% in early 2024 to 85%-90% in 2025, expected to reach 90%-95% in 2026 [5] - Major foreign institutions like Morgan Stanley and Livermore Securities led the way in underwriting and sponsoring Hong Kong IPOs [5] Industry Focus - The 2026 IPO market is anticipated to be dominated by technology sectors, particularly AI and biotech, reflecting China's advancements in these fields [7][10] - The proportion of companies currently filing for IPOs in AI and software technology is 22.88%, while biotech accounts for 17.75% [10] Notable Companies and Sponsors - The most anticipated IPOs for 2026 include companies like Kunlun Chip, Shangmi Technology, and Qunke Technology, focusing on AI and new economic sectors [14] - The leading sponsors for IPOs in 2025 were CICC with 41 projects, followed by CITIC Securities with 32 projects [4]

Core Viewpoint - In 2025, Hong Kong's stock market achieved a record-breaking IPO fundraising of $37.4 billion, marking a 231% year-on-year increase and surpassing the total of the previous three years combined, showcasing its dominance in the global market [1] IPO Market Performance - The TMT sector led the IPO fundraising with $34.5 billion, followed by the healthcare and biotechnology sector, which raised $15.6 billion, with biotechnology alone contributing $6.2 billion [1] - As of early February 2026, over 400 companies are queued for listing, with more than 50 targeting specific chapters for biotechnology and specialized technology [1] Top IPO Companies - The top three companies by fundraising in 2025 were CATL ($41.006 billion), Zijin Mining International ($28.732 billion), and SANY Heavy Industry ($15.471 billion), primarily from sectors like renewable energy, AI, software and hardware technology, pharmaceuticals, and consumer goods [2] Stock Performance Post-IPO - Newly listed stocks with fundraising of $100 million or more saw an average first-day price increase of 23.8% and an average one-month increase of 30.7%, marking the best performance in nearly two decades [5] Foreign Investment Trends - Long-term foreign investment in Hong Kong IPOs surged, with participation rates rising from 10%-15% in early 2024 to 85%-90% in 2025, with expectations to reach 90%-95% in 2026 [6] - Major foreign institutions like Morgan Stanley and Livermore Securities led the way in underwriting and sponsoring Hong Kong IPOs [6] Anticipated Future Trends - The 2026 IPO market is expected to be a significant year for technology, with a notable increase in companies from AI and biotechnology sectors [19] - The anticipated top ten companies for 2026 include Kunlun Chip, Sunmi Technology, and Qunhe Technology, reflecting a strong focus on AI and new economic sectors [19] Underwriters and Sponsors - In 2025, the top underwriters by project count were CICC (41 projects), CITIC Securities (32 projects), and Huatai Financial (22 projects) [4] - For the ongoing 2026 IPO applications, CICC and CITIC Securities are leading with a market share of 16.23% each [15] Sector Distribution of Upcoming IPOs - The distribution of companies currently in the IPO pipeline is as follows: AI and software technology (22.88%), healthcare and biotechnology (17.75%), and industrial (14.91%) [14]

Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock price drop, with a decline exceeding 70% following a notification from the Hong Kong Stock Exchange regarding insufficient operational levels and asset value to support continued listing [1][2]. Group 1: Company Announcement and Stock Performance - On November 14, 2025, the company received a letter from the Stock Exchange indicating that it failed to maintain sufficient operational levels and asset value, leading to a decision to suspend trading of its shares on November 26, 2025 [2][3]. - The company had previously announced a failed placement agreement to issue up to 145 million shares at HKD 0.415 per share, as the conditions precedent were not met by September 11, 2025 [1][3]. Group 2: Financial Performance - For the fiscal year ending March 31, 2025, the company reported a revenue of HKD 2.091 million, a year-on-year decrease of 68.28%, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [5]. - The basic earnings per share for the reporting period were -HKD 0.2001, with net cash flow from operating activities at -HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [5].

Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock crash, with a drop exceeding 70% due to regulatory actions from the Hong Kong Stock Exchange regarding its operational viability and asset value [2][5][9]. Company Announcement - On November 14, 2025, Starcoin Group received a notification from the Hong Kong Stock Exchange stating that it failed to maintain sufficient operational levels and asset value, leading to a suspension of its shares on November 26, 2025, unless a review is requested [4][6]. - The company announced that a planned share placement of up to 145 million shares at HKD 0.415 per share has become void due to unmet conditions by September 11, 2025, terminating all responsibilities between the placement agent and the company [2][7]. Financial Performance - For the fiscal year ending March 31, 2025, Starcoin Group reported a revenue of HKD 2.091 million, a decline of 68.28% year-on-year, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [10]. - The basic earnings per share for the reporting period was -HKD 0.2001, with a net cash outflow from operating activities of HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [10]. Company Background - Starcoin Group operates in the pharmaceutical and biotechnology sector, with five divisions including genetic testing services, bioproduct distribution, beauty equipment trade, securities investment, and research on oral insulin products [9]. - The company had previously seen a significant stock price increase of nearly 100% during June to July 2025 before entering a downward trend [9].